Literature DB >> 12859948

Protein kinase C mu is down-regulated in androgen-independent prostate cancer.

Meena Jaggi1, Prema S Rao, David J Smith, George P Hemstreet, K C Balaji.   

Abstract

Progression to androgen independence (AI) is the main cause of death in prostate cancer. Our prior differential gene expression studies by microarray analysis in progressive prostate cancer cell line model identified dysregulation of protein kinase C mu (PKCmu) expression in prostate cancer. In this study, quantitative ribonuclease protection assay and immunoblot analysis demonstrate down regulation of PKCmu at transcription and translational level, respectively, in AI C4-2 cells compared to its parental androgen dependent (AD) LNCaP prostate cancer cells. Significantly lower PKCmu kinase activity was confirmed in C4-2 cells by in vitro kinase assay. Immunohistochemical studies of prostate cancer tissue from patient progressing to AI prostate cancer demonstrated that PKCmu expression is decreased in 100% of AI human prostate cancers. The consistent down regulation of PKCmu in cell line models and human prostate cancer tissues suggests a possible functionally significant role for PKCmu in progression to AI in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12859948     DOI: 10.1016/s0006-291x(03)01161-6

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

Review 1.  Protein kinase D as a potential new target for cancer therapy.

Authors:  Courtney R LaValle; Kara M George; Elizabeth R Sharlow; John S Lazo; Peter Wipf; Q Jane Wang
Journal:  Biochim Biophys Acta       Date:  2010-05-24

2.  Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation.

Authors:  Ninel Azoitei; Alexander Kleger; Nina Schoo; Dietmar Rudolf Thal; Cornelia Brunner; Ganesh Varma Pusapati; Alina Filatova; Felicitas Genze; Peter Möller; Til Acker; Rainer Kuefer; Johan Van Lint; Heinrich Baust; Guido Adler; Thomas Seufferlein
Journal:  Neuro Oncol       Date:  2011-07       Impact factor: 12.300

3.  Neuregulin mediates F-actin-driven cell migration through inhibition of protein kinase D1 via Rac1 protein.

Authors:  Heike Döppler; Ligia I Bastea; Tim Eiseler; Peter Storz
Journal:  J Biol Chem       Date:  2012-11-12       Impact factor: 5.157

4.  Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101.

Authors:  Sahra Borges; Edith A Perez; E Aubrey Thompson; Derek C Radisky; Xochiquetzal J Geiger; Peter Storz
Journal:  Mol Cancer Ther       Date:  2015-04-07       Impact factor: 6.261

Review 5.  Emerging roles of protein kinase D1 in cancer.

Authors:  Vasudha Sundram; Subhash C Chauhan; Meena Jaggi
Journal:  Mol Cancer Res       Date:  2011-06-16       Impact factor: 5.852

Review 6.  Phosphorylation: Implications in Cancer.

Authors:  Vishakha Singh; Mahendra Ram; Rajesh Kumar; Raju Prasad; Birendra Kumar Roy; Kaushal Kumar Singh
Journal:  Protein J       Date:  2017-02       Impact factor: 2.371

7.  Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility.

Authors:  Courtney R Lavalle; Karla Bravo-Altamirano; Karthik V Giridhar; Jun Chen; Elizabeth Sharlow; John S Lazo; Peter Wipf; Q Jane Wang
Journal:  BMC Chem Biol       Date:  2010-05-05

Review 8.  Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer.

Authors:  Nisha Durand; Sahra Borges; Peter Storz
Journal:  Cell Mol Life Sci       Date:  2015-08-08       Impact factor: 9.261

9.  A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells.

Authors:  Sahra Borges; Heike R Döppler; Peter Storz
Journal:  Breast Cancer Res Treat       Date:  2014-02-08       Impact factor: 4.872

10.  Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion.

Authors:  Tim Eiseler; Heike Döppler; Irene K Yan; Steve Goodison; Peter Storz
Journal:  Breast Cancer Res       Date:  2009-02-25       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.